The commercialisation of StemPrintER and its next generation derivative SPARE, the multi-gene prognostic assay intended for the prediction of risk of recurrence in luminal, ER+/HER2- breast cancer patients.
Multigene prognostic tests can assist decision making on treatments, differentiating low risk patients who could be spared chemotherapy from higher risk patients who might benefit from chemotherapy or prolonged endocrine treatments.
StemPrintER is a multi-gene prognostic assay intended to predict the risk of recurrence of ER+/HER2- breast cancer, and Spare, a derivative of StemPrintER, combines StemPrintER with two clinical markers. This gives a more refined risk model.
These assays are intended for the prediction of the risk of recurrence of breast cancer, based on the detection of 20 stem cell markers. The assay has been evaluated in an initial retrospective validation study using a consecutive cohort of approximately 2,400 patients with breast cancer. Subsequently, StemPrintER has been further validated in an independent retrospective cohort of more than 800 ER+/HER2- postmenopausal patients from the TransATAC trial.
Endocrine receptor-positive (ER+) breast cancers make up most breast cancer cases, however display significant variability in clinical behaviour, this makes prognosis and therapy response challenging. Although the overall prognosis of patients is good, a significant proportion of these women will experience distant recurrence in the first 10 years post-surgery.
For patients who also have a negative HER2 status (HER2-) and risk of recurrence, the standard of care is endocrine therapy, with the addition of chemotherapy in patients. However, these parameters are often insufficient to predict risk of recurrence in ER+/HER2- breast cancer patients, and consequently, these patients are either over- or under-treated.
Accustem anticipates this prognostic test to be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis.